A Retrospective Study on Predicting Recurrence of Intermediate-Stage Hepatocellular Carcinoma After Radical Therapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-1247133
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatol. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• De Carlis L, Di Sandro S, Centonze L, et al. Liver-allocation policies for patients affected by HCC in Europe. Curr Transplant Rep. 2016;3(4):313–318. doi:10.1007/s40472-016-0117-6
   PubMedGoogle Scholar
• Chang WT, Kao WY, Chau GY, et al. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012;152(5):809–820. doi:10.1016/j.surg.2012.03.024
   PubMed Web of Science ®Google Scholar
• Garancini M, Pinotti E, Nespoli S, Romano F, Gianotti L, Giardini V. Hepatic resection beyond Barcelona clinic liver cancer indication: when and how. World J Hepatol. 2016;8(11):513–519. doi:10.4254/wjh.v8.i11.513
   PubMed Web of Science ®Google Scholar
• Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatol. 2015;62(2):440–451. doi:10.1002/hep.27745
   PubMed Web of Science ®Google Scholar
• Vitale A, Burra P, Frigo AC, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona clinic liver cancer stages: a multicentre study. J Hepatol. 2015;62(3):617–624. doi:10.1016/j.jhep.2014.10.037
   PubMed Web of Science ®Google Scholar
• Kapitanov T, Neumann UP, Schmeding M. Hepatocellular carcinoma in liver cirrhosis: surgical resection versus transarterial chemoembolization-a meta-analysis. Gastroenterol Res Pract. 2015;2015:696120. doi:10.1155/2015/696120
   PubMed Web of Science ®Google Scholar
• Lin CT, Hsu KF, Chen TW, et al. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34(9):2155–2161. doi:10.1007/s00268-010-0598-x
   PubMed Web of Science ®Google Scholar
• Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol. 2014;61(1):82–88. doi:10.1016/j.jhep.2014.03.012
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Tsuji K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer. 2019;8(2):121–129. doi:10.1159/000488778
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31(5):1031–1036. doi:10.1111/jgh.13250
   PubMed Web of Science ®Google Scholar
• Daniele B, Elba S, Capuano G, et al. The CLIP score: a new prognostic system for hepatocellular carcinoma. Hepatol. 1998;28(4):1.
   PubMed Web of Science ®Google Scholar
• Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54(3):419–425. doi:10.1136/gut.2003.035055
   PubMed Web of Science ®Google Scholar
• Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–1700.e1693. doi:10.1053/j.gastro.2014.02.032
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–359. doi:10.1055/s-0032-1329906
   PubMed Web of Science ®Google Scholar
• Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi’s subclassification (kinki criteria). Dig Dis. 2015;33(6):751–758. doi:10.1159/000439290
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Nouso K, et al. Proposed new sub-grouping for intermediate-stage hepatocellular carcinoma using albumin-bilirubin grade. Oncology. 2016;91(3):153–161. doi:10.1159/000447061
   PubMed Web of Science ®Google Scholar
• Mathew EN, Nadkarni N, Choo SP, et al. BCLC subclassification and tumour characteristics to provide prognostication of outcomes in an Asian population of locally advanced hepatocellular carcinoma treated using selective internal radiation therapy with yttrium-90. J clin oncol. 2018;36(4):443. doi:10.1200/JCO.2018.36.4_suppl.443
   Web of Science ®Google Scholar
• Giannini EG, Moscatelli A, Pellegatta G, et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol. 2016;111(1):70–77. doi:10.1038/ajg.2015.389
   PubMed Web of Science ®Google Scholar
• Scaffaro LA. Survival rates according to Barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. World J Hepatol. 2015;7(3):628–632. doi:10.4254/wjh.v7.i3.628
   PubMedGoogle Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi:10.1016/S1470-2045(08)70284-5
   PubMed Web of Science ®Google Scholar
• Kim JH, Shim JH, Lee HC, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017;37(12):1861–1868. doi:10.1111/liv.13487
   PubMed Web of Science ®Google Scholar
• Wang XH, Liu QB, Xiang CL, et al. Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma. Int J Cancer Res. 2021;149(1):127–138. doi:10.1002/ijc.33516
   Web of Science ®Google Scholar
• Zhang W, Wang Y, Dong X, et al. Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma. Biosci Trends. 2022;15(6):397–405. doi:10.5582/bst.2021.01517
   PubMed Web of Science ®Google Scholar
• Wang X, Mao M, He Z, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Bio Sci. 2019;15(1):221–228. doi:10.7150/ijbs.28720
   Google Scholar
• Su K, Huang W, Li X, et al. Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocell Carcinoma. 2023;10:69–79. doi:10.2147/JHC.S398632
   PubMed Web of Science ®Google Scholar
• Wang D, Hu X, Xiao L, et al. Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC. World J Gastrointest Surg. 2021;25(2):421–427. doi:10.1007/s11605-019-04492-7
   Google Scholar